Latest Commercial Scale Up News

Zoono Group has secured its first major commercial orders worth NZ$600,000 from Sharpak under an exclusive UK soft fruits packaging contract, marking a key step in scaling its antimicrobial coating technology in international markets.

NoviqTech's Coralia has kicked off a comprehensive trial converting invasive Chinese Apple trees into biochar at its Great Barrier Reef project, aiming to validate carbon removal methods and support institutional partnerships.

Viridis Mining has produced its first batch of high-grade Mixed Rare Earth Carbonate at its Poços de Caldas Demonstration Plant, advancing key milestones for the Colossus Project and setting the stage for commercial-scale rare earth production.

Delorean’s flagship SA1 Salisbury bioenergy plant is 75% complete, poised to start injecting renewable biomethane into Adelaide’s gas network by November 2026, marking a first in Australia for commercial and industrial organic waste processing.

Wide Open Agriculture has agreed with Curtin University to replace its tiered royalty structure with a single 3.5% flat royalty on net sales, streamlining financial planning and enhancing commercial scalability for its lupin protein technology.

Vitrafy Life Sciences has achieved a major validation milestone with US Army-backed Phase II results showing its no-wash platelet cryopreservation protocol delivers 94% post-thaw recovery, outperforming existing standards and advancing FDA registration plans.

Papyrus Australia has fulfilled a critical contract milestone by delivering 200 biodegradable Collar Keeper product samples to TBS Mining Solutions, enabling the next phase of product testing despite a slight delay.

Gold Hydrogen is accelerating Helium development at its Ramsay Project, leveraging exceptional purity results and independent modelling amid a tightening global Helium supply.

Cleo Diagnostics has laid out a clear U.S. reimbursement pathway for its ovarian cancer test, leveraging an existing CPT code to enable early market entry and data collection ahead of FDA clearance.

OncoSil Medical has clinched TGA approval for its OncoSil™ device, the first Class III medical device targeting pancreatic tumours in Australia, paving the way for local commercialisation and enhanced patient access.

Electro Optic Systems (ASX:EOS) has closed its three-year turnaround and is now poised for growth, backed by a landmark high-energy laser contract, a major European acquisition, and a $175 million capital raise.

WA Kaolin has successfully recapitalised its balance sheet by approximately A$16.1 million through a partially underwritten entitlement offer and significant debt reduction, positioning the company for operational growth at its Wickepin kaolin project.